Art. -Nr.: HY-P991481

S-531011

Kundenbewertung

Based on 1 Customer Validation

S-531011 is a high-affinity, selective, and reversible CCR8 ligand with antibody-dependent cellular cytotoxicity (ADCC) against CCR8-expressing cells. S-531011 induces the death of tumor-infiltrating CCR8⁺regulatory T cells while preserving regulatory T cells in peripheral blood, thereby reinvigorating anti-tumor immunity. The combination of S-531011 with anti-PD-1 antibody effectively inhibits tumor growth, and S-531011 can be used for research on advanced solid tumors and various cancers including non-small cell lung cancer, ovarian cancer, colon cancer, breast cancer, and pancreatic ductal adenocarcinoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.38%
Molecular Weight:148.11 kDa

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

S-531011 Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Anwendung
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target^[1]

CCR8

18.6 pM (Kd)

Alle CCR Isoform-spezifische Produkte anzeigen :

In Vitro

S-531011 binds to CCR8 with an in vitro-measured association rate constant of 11.9 L/nmol/hr and a calculated dissociation rate constant of 6.65 1/hr^[2].
S-531011 (0.08-0.3 nmol/L; overnight) binds specifically and with high affinity to human CCR8 (K_d = 18.6 pmol/L) and its CCR8^A27G variant (K_d = 26.4 pmol/L) expressed on HEK293T cells, with no cross-reactivity to other tested receptors^[3].
S-531011 (up to 300 μg/mL; 2 hours) lacks CDC activity against Ramos-hCCR8 cells, with no measurable EC₅₀ at concentrations up to 300 μg/mL^[3].
S-531011 (0.001-10 μg/mL; overnight) selectively depletes tumor-infiltrating Tregs, but not Tconv cells, in human NSCLC and ovarian cancer tissues via ADCC, whereas Mogamulizumab (HY-P99253) depletes both populations^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

S-531011 (0.15-15 mg/kg; i.v.; 2 doses (days 4 and 11 post tumor inoculation)) induces potent dose-dependent antitumor activity in CT26.WT tumor-bearing hCCR8 KI mice, with significant tumor volume reduction observed at doses of 0.15, 5, and 15 mg/kg^[3].
S-531011 (100 μg/mouse; i.v.; 2 doses (days 5 and 12 post tumor inoculation)) induces potent antitumor activity in EMT6 tumor-bearing hCCR8 KI mice, with significantly greater tumor volume reduction than vehicle or anti-mouse PD-1 antibody treatment^[3].
S-531011 (10 mg/kg; i.v.; single dose (day 5 post tumor inoculation)) enhances the antitumor activity of anti-mouse PD-1 antibody in CT26.WT tumor-bearing hCCR8 KI mice without observable adverse effects^[3].
S-531011 (0.05-5 mg/kg; i.v.; single dose (day 8 post tumor inoculation)) induces dose-dependent depletion of tumor-infiltrating CCR8⁺ Tregs in CT26.WT tumor-bearing hCCR8 KI mice, with effects lasting at least 7 days after a single dose^[3].
S-531011 (0.05-0.5 mg/kg; i.v.; single dose (day 8 post tumor inoculation)) induces dose-dependent depletion of tumor-infiltrating CCR8⁺ Tregs in Colon26 tumor-bearing hCCR8 KI mice 4 days after a single dose^[3].
S-531011 (0.05-0.5 mg/kg; i.v.; single dose (day 8 post tumor inoculation)) induces dose-dependent depletion of tumor-infiltrating CCR8⁺ Tregs in EMT6 tumor-bearing hCCR8 KI mice 4 days after a single dose^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

humanized CCR8 knock-in (hCCR8 KI) (female, CT26.WT colorectal cancer cells subcutaneously implanted)^[3]
Dosage:

0.15 mg/kg; 0.5 mg/kg; 1.5 mg/kg; 5 mg/kg; 15 mg/kg
Administration:

i.v.; 2 doses (days 4 and 11 post tumor inoculation)
Result:

Reduced tumor volumes significantly in the 0.15, 5, and 15 mg/kg groups compared with isotype control antibody group (P < 0.05, P < 0.001, P < 0.001, respectively, on day 19 after inoculation).

Animal Model:

humanized CCR8 knock-in (hCCR8 KI) (female, EMT6 mammary carcinoma cells subcutaneously implanted)^[3]
Dosage:

100 μg/mouse
Administration:

i.v.; 2 doses (days 5 and 12 post tumor inoculation)
Result:

Reduced tumor volumes significantly compared with vehicle control group (P < 0.0001) and anti-mouse PD-1 antibody-treated group (P < 0.05) on day 28 after implantation.

Animal Model:

humanized CCR8 knock-in (hCCR8 KI) (female, CT26.WT colorectal cancer cells subcutaneously implanted)^[3]
Dosage:

10 mg/kg
Administration:

i.v.; single dose (day 5 post tumor inoculation)
Result:

Suppressed tumor volume significantly when combined with anti-mouse PD-1 antibody compared with S-531011 alone (P < 0.05) on day 21 after inoculation.
Caused no reduction in body weight or worsening of general condition.

Animal Model:

humanized CCR8 knock-in (hCCR8 KI) (female, CT26.WT colorectal cancer cells subcutaneously implanted)^[3]
Dosage:

0.05 mg/kg; 0.5 mg/kg; 5 mg/kg
Administration:

i.v.; single dose (day 8 post tumor inoculation)
Result:

Reduced the proportion of CCR8⁺ Tregs relative to total Tregs in a dose-dependent manner at 4 and 7 days post-administration (P < 0.001 and P < 0.0001 for all doses vs. isotype control).

Animal Model:

humanized CCR8 knock-in (hCCR8 KI) (female, Colon26 colorectal cancer cells subcutaneously implanted)^[3]
Dosage:

0.05 mg/kg; 0.5 mg/kg
Administration:

i.v.; single dose (day 8 post tumor inoculation)
Result:

Reduced the proportion of CCR8⁺ Tregs relative to total Tregs in a dose-dependent manner (P < 0.05 for 0.05 mg/kg, P < 0.01 for 0.5 mg/kg vs. saline) 4 days after administration.

Animal Model:

humanized CCR8 knock-in (hCCR8 KI) (female, EMT6 mammary carcinoma cells subcutaneously implanted)^[3]
Dosage:

0.05 mg/kg; 0.5 mg/kg
Administration:

i.v.; single dose (day 8 post tumor inoculation)
Result:

Reduced the proportion of CCR8⁺ Tregs relative to total Tregs in a dose-dependent manner (P < 0.05 for 0.05 mg/kg, P < 0.01 for 0.5 mg/kg vs. saline) 4 days after administration.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Gene ID

1237 [NCBI]

Accession

P51685

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

IgG1-kappa
Product Image

Anwendung

ELISA, FACS, Functional assay

Chemical Information

Appearance Liquid
Molecular Weight 148.11 kDa
Color Colorless to light yellow
SMILES

[S-531011]
Versand

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (267 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

Verweise

[1]. Kobayashi H, et al. Epitope mapping of an anti-mouse CCR8 monoclonal antibody C8Mab-2 using flow cytometry[J]. Monoclonal Antibodies in Immunodiagnosis & Immunotherapy, 2024, 43(4): 101-107.

[2]. Yamaguchi D, et al. Modeling for prediction of CCR8 receptor occupancy in human tumor tissues after dosing of S-531011, a humanized anti-CCR8 monoclonal antibody[C]//American Conference of Pharmacometrics. International Society of Pharmacometrics, 2026: S-036.

[3]. Nagira Y, et al. S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells. Mol Cancer Ther. 2023;22(9):1063-1072. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

S-531011

Antibody Inhibitor Library

Alle CCR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

S-531011 Related Classifications

HY-P991481 Related Classifications